We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...

Recently, Pfizer found itself in the agency's crosshairs thanks to one of its M&A plays. Now, Pfizer—which purchased neuroscience specialist Biohaven for $11.6 billion in 2022—is committing ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...

Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients ...

NEW YORK, Jan 24 (Reuters) - Pfizer (PFE.N), opens new tab will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Pfizer PFE-0.43%decrease; red down pointing triangle will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs ...

US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, moved closer to securing the top health job on ...

The European Union has rubber-stamped its order for a further 300 million doses of Pfizer/BioNTech’s COVID-19 vaccine, according to press reports. Citing a European Commission spokesperson ...

Dr. Paul Streck, Head of R&D at PepGen, stated that all treatment-related adverse events in CONNECT1 have been mild and the safety profile of PGN-EDO51 appears favorable. The company remains ...